Skip to content
Biodatica
Start free

Boston Scientific Corporation

Denver, Colorado

OncologymicrobiomeGrant-onlyListed · BSX

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Compare Sign in to watch

What changed

Study registered, no phase assigned: RESTOREGI Study: Regenerative Endoscopic Stromal Therapy: Outcomes and Risk Factor Evaluation in GI Fistulas

3w agoTrial registeredJun 24, 2026Source filing (opens the source filing in a new tab)

Momentum

92no change

Momentum 92 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Grant-only

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    NA registered

    Jun 15, 2026

    Fistula, Regenerative Medicine, Stromal Vascular Fraction · NOT_YET_RECRUITING · sponsor: Asian Institute of Gastroenterology, India · RESTOREGI Study: Regenerative Endoscopic Stromal Therapy: Outcomes and Risk Factor Evaluation in GI Fistulas

    ClinicalTrials.gov · NCT07661043 (opens the source filing in a new tab)

  2. Trial

    NA registered

    May 20, 2026

    Achalasia Cardia, GERD (Gastroesophageal Reflux Disease) · ACTIVE_NOT_RECRUITING · sponsor: Asian Institute of Gastroenterology, India · Biological Optimization Versus Standard Care in Post-POEM Achalasia Patients (BIO-POEM)

    ClinicalTrials.gov · NCT07620899 (opens the source filing in a new tab)

  3. Trial

    Study registered

    Feb 5, 2026

    Colorectal Cancer · RECRUITING · sponsor: Asian Institute of Gastroenterology, India · A Single Center Evaluation of AI Enabled SureForm Robotic Stapler (SureformTM) Compared to Conventional Stapler for Colorectal Cancer Procedures

    ClinicalTrials.gov · NCT07371832 (opens the source filing in a new tab)

  4. Trial

    Study registered

    Jan 15, 2026

    Stress Ulcers, Reflux Episodes · NOT_YET_RECRUITING · sponsor: Asian Institute of Gastroenterology, India · Efficacy and Safety of Esomeprazole 40 mg IV in Post-Surgical Patients Admitted to the ICU

    ClinicalTrials.gov · NCT07399054 (opens the source filing in a new tab)

  5. Trial

    NA registered

    Jun 1, 2025

    Pancreatectomy, Distal Pancreatectomy (DP), Pancreatic Neoplasms, Pancreatic Adenoma, Pancreatic Cyst, Pancreatic Cystadenoma, Surgery, Minimally Invasive Surgical Technique, Minimally Invasive Distal Pancreatectomy, Minimally Invasive Surgery · RECRUITING · sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Laparoscopic Versus Robot-assisted Left-sided Pancreatectomy for Benign and Pre-malignant Lesions (DIPLOMA-3)

    ClinicalTrials.gov · NCT06939023 (opens the source filing in a new tab)

  6. Trial

    Study registered

    Feb 29, 2024

    Duodenal Neuroendocrine Tumor · COMPLETED · sponsor: Asian Institute of Gastroenterology, India · Efficacy of Endoscopic Band Ligation (DEBL) for Duodenal Neuroendocrine Neoplasms(dNENs)

    ClinicalTrials.gov · NCT06790056 (opens the source filing in a new tab)

  7. Trial

    Study registered

    Mar 20, 2019

    Intraductal Papillary Mucinous Neoplasm · ACTIVE_NOT_RECRUITING · sponsor: Boston Scientific Corporation · Intra-operative Pancreatoscopy in Patients With IPMN

    ClinicalTrials.gov · NCT03729453 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources